An interventional study of MobiDig in Heart Failure, sponsored by German Heart Institute. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by German Heart Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by German Heart Institute — 3 open to participants now, 4 under way, none of them phase 3. Heart Failure · German Heart Institute.
Among the 11 studies in Heart Failure by German Heart Institute, this one is one of 2 that started in 2022, is one of 4 with no phase, and was the 9th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →3 of the 11 studies in Heart Failure by German Heart Institute are open now, in 1 country. Recruiting first, the newest first:
German Heart Institute · Sites in Germany
Ages 40–69
German Heart Institute · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 50 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 60 across the 5 interventional studies, 265 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
German Heart Institute is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
1 of the studies in Heart Failure by German Heart Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07185100German Heart InstituteDetermination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure by German Heart Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive/rehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg.
The aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 patients will have access to a mobile phone application for 3 months.
Other: MobiDig
The application will contain the following modules: 1. information and knowledge about heart failure; 2. vital sign diary, which can be sent to the certified HFU 3. pedometer (individualized step-goal), cardiac home training videos 4. "frequently asked questions" and connection to a certified HFU provider by a heart failure hotline
Acceptance of the application
The acceptence of the application will be measured by the User Experience Questionnaire. It consists of 9 items that can be rated on a 7-point Likert scale. -3 (fully agree with negative term) to +3 (fully agree with positive term). A higher total score means a better outcome.
Time frame: 3 months
Change in quality of life
Quality of life measured by Kansas City Cardiomyopathy Questionnaire using the validated 12-item version which has been described by Spertus et Jones (doi: 10.1161/CIRCOUTCOMES.115.001958.) A higher score means a better outcome.
Time frame: Baseline and 3 months
Patient reported outcomes
Health-related quality of life will be measured by the "Patient Related Outcome and Measurement Information System" (PROMIS) test. Including 23 items that will be analyzed via Likert scale 1 (impossible/never) to 5 (no limitations/very good). A higher score means a better outcome.
Time frame: Baseline and 3 months
Change in symptoms of heart failure
Symptoms of heart failure will be assessed by the New York Heart Association functional class. Consisting of four classes (I-IV), the higher, the worse the outcome.
Time frame: Baseline and 3 months
Change in six-minute walk distance
Functional capacity will be assessed by the 6-minute walk test
Time frame: Baseline and 3 months
Change in daily walking distances
Functional capacity will be assessed by the steps taken within 24 hours (pedometry).
Time frame: Baseline and 3 months
Change in heart failure biomarker
Heart failure severity will be assessed by the biomarker NT-proBNP.
Time frame: Baseline and 3 months
Number of hospitalizations
Number of hospitalizations for heart failure will be assessed.
Time frame: 3 months
Length of hospitalizations
Length of in-hospital stay of hospitalizations for heart failure will be assessed.
Time frame: 3 months
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Jan 2025, 30 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 30 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
German Heart Institute